ArticleAmerican journal of translational research2013

An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI).

Xiang Ling et al.PubMed ↗Full text ↗

No numbers read from the abstract.